A scientific study published by the prestigious NUTRAfoods Journal, demonstrates the efficacy of the phytocomplex from Ascophyllum nodosum in helping to treat metabolic syndrome.
Ischaemic heart disease is now the leading cause of premature death in the Western world, with an annual toll, in human lives, in excess of 7 million. Among the main risk factors are obesity and dyslipidemia, that is to say the increase of triglycerides and LDL cholesterol in the blood. The cardiovascular threat can be significantly reduced with a good diet, regular physical activity and a healthy lifestyle, possibly supplemented by functional foods and supplements that have a specific action.
This is the case with the phytocomplex Ascophyllum nodosum, the Arctic seaweed harvested and processed in a sustainable and innovative way in Norway's more northern regions.
Rich in iodine, natural anti-oxidants, algal carotenoids, polyphenols and fucoidans, this sea weed has been processed for more than 75 years by Algea, a subsidiary of the Valagro Group. At the forefront of innovation and respect for the environment, Valagro's research has perfected the quality of Algea products using its own exclusive Geapower technology. Some of the outstanding results achieved include AlgeaFood Phyto, a natural ingredient for human nutrition that encourages the reduction of abdominal fat and the maintenance of correct trigylceride levels in the blood.
Evidence of this is provided in a detailed study published in the prestigious quarterly digital edition of the NUTRAfoods Journal dedicated to nutraceuticals, supplements and functional foods in general, with the aim of providing transparent information on these topics, that is both timely and scientifically correct.
The study, (conducted by a team of scientists from the Mediterranean Nuerological Institute NEUROMED, the Veneziale hospital of Isernia, the Catholic University of the Sacred Heart of Campobasso and Epicomed Research) spanned a 6 week period and involved 43 healthy adults, 24 of whom were women between the ages of 21 and 63. A number of them was given a placebo, whilst others took two capsules of AlgeaFood Phyto daily.
The meticulous methodology applied to the study, published in full on the NUTRAfoods Journal, has allowed an accurate measurement of the results of the two groups of patients. What was established, in particular, was AlgeaFood Phyto’s ability of to maintain the level of triglycerides in the blood (minus 5% compared to the placebo group). What renders these findings particularly significant is the absence of any health side effects, thus ensuring the product's total safety.
The study demonstrates, at the same time, the Valagro Group's commitment to products that are increasingly more effective, innovative and respectful of the environment and human health.